ArticleSeminars in arthritis and rheumatism2020
Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.
Article in Seminars in arthritis and rheumatism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 175 citations in OpenAlex.
- Efficacy of blinatumomab for dermatomyositis/SLE overlap syndrome occurring after allogeneic hematopoietic stem cell transplant performed for acute lymphoblastic leukemia.Bone marrow transplantation · 2026Article
- From Scrotal Ulcer to Respiratory Failure: An Unusual Presentation of Anti-MDA5 Dermatomyositis.International journal of rheumatic diseases · 2026Article
- MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD.Stem cell research & therapy · 2026Review
- Extracorporeal membrane oxygenation for idiopathic inflammatory myopathy-associated interstitial lung disease: a narrative review.Journal of thoracic disease · 2026Review
- Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials.Clinical and experimental rheumatology · 2026Review
- The clinical values of laboratory inflammatory and composite indices in predicting rapidly progressive interstitial lung disease and prognosis in anti-MDA5 dermatomyositis patients.Clinical rheumatology · 2026Article
- Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile.Journal of internal medicine · 2026Article
- Article
- Pathogenesis and Treatment of Interstitial Lung Disease Accompanied by Anti-melanoma Differentiation-associated Gene 5-positive Idiopathic Inflammatory Myopathies.Internal medicine (Tokyo, Japan) · 2026Review
- Case Report: Glucocorticoids with Early Aggressive Rituximab and Upadacitinib regimen in the treatment of three patients with anti-MDA5 dermatomyositis-associated interstitial lung disease.Frontiers in medicine · 2026Article
- Clinical phenotype and prognostic determinants of spontaneous pneumomediastinum in anti-MDA5 antibody-positive dermatomyositis.Frontiers in immunology · 2026Article
- Prognostic value of HRCT-based risk stratification for acute/subacute progression in polymyositis/dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Clinical features and prognostic factors of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease with spontaneous mediastinal emphysema: a retrospective case series of nine patients.Frontiers in medicine · 2026Article
- Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease.Arthritis research & therapy · 2025Article
- Tacrolimus Trough Concentration-Escalating Bipartite Therapy (Glucocorticoids Combined With Tacrolimus) for Refractory MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Pneumonia.Immunity, inflammation and disease · 2025Article
- Article
- Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review.Rheumatology (Oxford, England) · 2025Review
- Anti- Melanoma Differentiation-Associated Gene 5 Antibody Positive Dermatomyositis: Recent Progress in Pathophysiology and Treatment.Current rheumatology reports · 2025Review
- Melanoma Differentiation-associated Gene 5-Positive Rapidly Progressive Interstitial Lung Disease Successfully Treated with Tofacitinib.Internal medicine (Tokyo, Japan) · 2025Article
- Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study.BMC pulmonary medicine · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 4 countries.
Funding
Abstract
objectivesThe study aimed to develop evidence-based recommendations for the treatment of rapidly progressive interstitial lung disease (RPILD) associated with the anti-Melanoma Differentiation-Associated Gene 5-positive dermatomyositis (DM) syndrome.
methodsThe task force comprised an expert panel of specialists in rheumatology, intensive care medicine, pulmonology, immunology, and internal medicine. The study was carried out in two phases: identifying key areas in the management of DM-RPILD syndrome and developing a set of recommendations based on a review of the available scientific evidence. Four specific questions focused on different treatment options were identified. Relevant publications in English, Spanish or French up to April 2018 were searched systematically for each topic using PubMed (MEDLINE), EMBASE, and Cochrane Library (Wiley Online). The experts used evidence obtained from these studies to develop recommendations.
resultsA total of 134 studies met eligibility criteria and formed the evidentiary basis for the recommendations regarding immunosuppressive therapy and complementary treatments. Overall, there was general agreement on the initial use of combined immunosuppressive therapy. Combination of high-dose glucocorticoids and calcineurin antagonists with or without cyclophosphamide is the first choice. In the case of calcineurin antagonist contraindication or treatment failure, switching or adding other immunosuppressants may be individualized. Plasmapheresis, polymyxin B hemoperfusion and/or intravenous immunoglobulins may be used as rescue options. ECMO should be considered in life-threatening situations while waiting for a clinical response or as a bridge to lung transplant.
conclusionsThirteen recommendations regarding the treatment of the anti-MDA5 positive DM-RPILD were developed using research-based evidence and expert opinion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.